Skye Bioscience wins jury verdict in former employee's whistleblower lawsuit
A jury sided with Skye Bioscience on all claims in a retrial of a former employee's Sarbanes-Oxley retaliation suit, the company disclosed in an 8-K filed November 12, 2026.
Skye Bioscience, Inc. filed a Form 8-K dated November 12, 2026, reporting that an event occurring on November 10, 2026 had taken place: a jury verdict in litigation brought by a former employee.
The case, Wendy Cunning vs Skye Bioscience, Inc., filed in the U.S. District Court for the Central District of California, alleged violation of whistleblower protections under the Sarbanes-Oxley Act of 2002 and retaliation under California law tied to actions during the plaintiff's employment from March 2018 to July 2019.1 The suit had previously been disclosed in the company's 10-Q filed August 14, 2026. The complaint had sought unspecified economic and non-economic losses, as well as attorneys' fees.1
According to the filing, on November 10, 2026, following a retrial in the District Court, the jury returned a unanimous verdict in favor of the Company on all claims.1 The company said it expects judgment to be entered by the District Court in due course.1 The plaintiff may file post-trial motions or appeal, and the company said it cannot predict whether that will happen or the outcome of any such motion or appeal.1
The same 8-K separately addressed the company's pending acquisition of Redx Pharma Limited, noting that Skye has filed a preliminary proxy statement with the SEC related to the proposed transaction, with a definitive version to follow for stockholders.1 The filing's disclosures on the litigation outcome were made under Item 8.01, Other Events, and signed by Chief Executive Officer Punit Dhillon on November 12, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.